Education
About Us
Working with TipRanks
Follow Us
COMPASS Pathways (CMPS)
NASDAQ:CMPS
CMPS Stock Chart & Stats
$7.35
-$0.42(-9.17%)
At close: 4:00 PM EST
$7.35
-$0.42(-9.17%)
Day’s Range― - ―
52-Week Range$2.25 - $8.20
Previous CloseN/A
Volume477.34K
Average Volume (3M)1.30M
Market Cap
$701.77M
Enterprise Value$395.15M
Total Cash (Recent Filing)$185.94M
Total Debt (Recent Filing)$35.18M
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Feb 26, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.44
Shares Outstanding96,017,044
10 Day Avg. Volume1,713,519
30 Day Avg. Volume1,298,266
Financial Highlights & Ratios
PEG Ratio1.91
Price to Book (P/B)1.65
Price to Sales (P/S)0.00
P/FCF Ratio-2.14
Enterprise Value/Market Cap0.56
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.71
Forecast
1Y Price Target
$17.67Price Target Upside140.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.84
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial InfrastructureAbility to leverage existing interventional psychiatry sites and trained provider networks from prior psychedelic programs should accelerate site readiness and lower adoption barriers for COMP360.
Regulatory ProgressPositive feedback from regulators on pragmatic trial designs that enroll patients resembling real-world post-traumatic stress disorder populations strengthens the regulatory pathway for COMP360.
Reimbursement MechanicsNew procedural billing codes and the option for monitoring by a broader licensed healthcare workforce improve clinic economics and make reimbursement more feasible for COMP360 treatments.
Bears Say
Competitive And Safety PressuresA promising rival candidate with strong efficacy data and potential safety concerns could shift prescriber and payer preferences, intensifying competitive pressure on market share.
Operational ScalabilityExtended single-session monitoring requirements create uncertainty about clinic throughput and staffing scalability, which could hinder broader commercial roll-out.
Trial Integrity RiskPrior patient experience with psychedelic medicines may compromise blinding in PTSD trials, creating risks for trial conduct and the perceived robustness of efficacy results.
COMPASS Pathways News
CMPS FAQ
What was COMPASS Pathways’s price range in the past 12 months?
COMPASS Pathways lowest stock price was $2.25 and its highest was $8.20 in the past 12 months.
What is COMPASS Pathways’s market cap?
COMPASS Pathways’s market cap is $701.77M.
When is COMPASS Pathways’s upcoming earnings report date?
COMPASS Pathways’s upcoming earnings report date is Feb 26, 2026 which is in 39 days.
How were COMPASS Pathways’s earnings last quarter?
COMPASS Pathways released its earnings results on Nov 04, 2025. The company reported -$1.44 earnings per share for the quarter, missing the consensus estimate of -$0.395 by -$1.045.
Is COMPASS Pathways overvalued?
According to Wall Street analysts COMPASS Pathways’s price is currently Undervalued.
Does COMPASS Pathways pay dividends?
COMPASS Pathways does not currently pay dividends.
What is COMPASS Pathways’s EPS estimate?
COMPASS Pathways’s EPS estimate is -0.4.
How many shares outstanding does COMPASS Pathways have?
COMPASS Pathways has 96,017,044 shares outstanding.
What happened to COMPASS Pathways’s price movement after its last earnings report?
COMPASS Pathways reported an EPS of -$1.44 in its last earnings report, missing expectations of -$0.395. Following the earnings report the stock price went up 11.429%.
Which hedge fund is a major shareholder of COMPASS Pathways?
Currently, no hedge funds are holding shares in CMPS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
COMPASS Pathways Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.67 (140.41% Upside)
$17.67 (140.41% Upside)
Blogger Sentiment
Neutral
CMPS Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 498.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.8%
Last 30 Days ▲ 6.6%
Last 30 Days ▲ 6.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
115.54%
12-Months-Change
Fundamentals
Return on Equity
-205.19%
Trailing 12-Months
Asset Growth
3.34%
Trailing 12-Months
Company Description
COMPASS Pathways
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
CMPS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with significant progress in clinical trials, regulatory interactions, and launch preparations. While there was a decrease in cash reserves, the company maintains a strong cash position with a runway into 2027.View all CMPS earnings summariesCMPS Stock 12 Month Forecast
Average Price Target
$17.67
▲(140.41% Upside)
Technical Analysis
Cross Country Healthcare
―
Oncology Institute
―
Talkspace
―
InnovAge Holding
―
Agilon Health
―
Ownership Overview
0.37% Insiders
0.85% Mutual Funds
0.17% Other Institutional Investors
94.89% Public Companies and Individual Investors